Ovarian Cancer Clinical Trial

A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

Summary

Ovarian cancer is a heterogeneous disease, characterized by complex molecular and genetic changes. The high expression of vascular endothelial growth factor (VEGF) receptor, programmed death receptor ligands 1 (PD-L1) expression, and deoxyribonucleic acid (DNA) damage in ovarian tumors provide several targets for treatment and maintenance of disease response. Given the unmet medical need of participants with advanced or metastatic ovarian cancer, this study design will enable investigators to provide participants with current SOC for ovarian cancer for the duration of the study. This is a global, multicenter, randomized, double-blind, controlled Phase 3 study that will primarily compare progressive survival rate of PD-L1 positive patients and also to compare progression-free survival (PFS) of all participants with Stage III or IV high-grade nonmucinous epithelial ovarian cancer treated with platinum-based combination therapy, dostarlimab, and niraparib to SOC platinum-based combination therapy. The currently recommended SOC therapy for the first line treatment of Stage III or IV ovarian cancer is the combination of paclitaxel and carboplatin, with or without concurrent and maintenance bevacizumab. Participants will receive SOC during the chemotherapy Run-In period (cycle 1) before randomization to study treatment (cycle 2). Concurrent bevacizumab use must be determined prior to randomization at cycle 2. Approximately 1228 participants will be enrolled into the study and the duration of the study will be approximately 78 months.

View Eligibility Criteria

Eligibility Criteria

Inclusion criteria:

Participants must be female, >=18 years of age, able to understand the study procedures, and agree to participate in the study by providing written informed consent.
Participants with a histologically confirmed diagnosis of high-grade nonmucinous epithelial ovarian (serous, endometrioid, clear cell, carcinosarcoma, and mixed pathologies), fallopian tube, or peritoneal cancer that is Stage III or IV according to the International Federation of Gynecology and Obstetrics (FIGO) or tumor, node and metastasis staging criteria.
All participants with Stage IV disease are eligible. This includes those with inoperable disease, those who undergo primary debulking surgery (PDS) (R0 or macroscopic disease), or those for whom neoadjuvant chemotherapy (NACT) is planned.
Participants with Stage III are eligible if they meet protocol defined criteria.
Participants must provide a blood sample for circulating tumor deoxyribonucleic acid (ctDNA) homologous recombinant repair (HRR) testing at pre-screening or screening.
Participant must provide a minimum of 1 formalin-fixed paraffin embedded (FFPE) block slide at pre-screening or screening for PD-L1, homologous recombinant deficiency (HRD) testing.
Participants of childbearing potential must have a negative serum or urine pregnancy test (beta human chorionic gonadotropin) within 3 days prior to receiving the first dose of study treatment.
Participants must be postmenopausal, free from menses for >1 year, surgically sterilized, or willing to use highly effective contraception to prevent pregnancy or must agree to abstain from activities that could result in pregnancy throughout the study, starting with enrollment through 180 days after the last dose of study treatment.
Participants must have adequate organ function: Absolute neutrophil count (ANC) >=1500/micro liter (μL;) Platelet count >=100000/μL; Hemoglobin >=9 grams per deciliter (g/dL); Serum creatinine <=1.5 × upper limit of normal (ULN) or calculated creatinine clearance >=60 milliliters per minute (mL/min) using the Cockcroft-Gault equation; total bilirubin <=1.5 × ULN or direct bilirubin <=1.5 × ULN; AST and ALT <=2.5 × ULN unless liver metastases are present, in which case they must be <=5 × ULN.
Participants must have an ECOG score of 0 or 1.
Participants must have normal blood pressure (BP) or adequately treated and controlled hypertension (systolic BP <=140 millimeters of mercury (mmHg) and/or diastolic BP <=90 mmHg).
Participants must agree to complete health related quality of life (HRQoL) questionnaires throughout the study.
Participants must be able to take oral medication.

Exclusion Criteria:

Participant has mucinous, germ cell, transitional cell, or undifferentiated tumor.
Participant has low-grade or Grade 1 epithelial ovarian cancer.
Participant has not adequately recovered from prior major surgery.
Participant is pregnant or is expecting to conceive children while receiving study drug or for up to 180 days after the last dose of study drug. Participant is breastfeeding or is expecting to breastfeed within 30 days of receiving the final dose of study drug (women should not breastfeed or store breastmilk for use, during niraparib treatment and for 30 days after receiving the final dose of study treatment).
Participant has known active central nervous system metastases, carcinomatous meningitis, or both.
Participant has clinically significant cardiovascular disease.
Participant has a bowel obstruction by clinical symptoms or computed tomography (CT) scan, subocclusive mesenteric disease, abdominal or gastrointestinal fistula, gastrointestinal perforation, or intra-abdominal abscess.
Participant has any known history or current diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
Participant has been diagnosed and/or treated with any therapy for invasive cancer <5 years from study enrollment, completed adjuvant chemotherapy and/or targeted therapy (example, trastuzumab) less than 3 years from enrollment, or completed adjuvant hormonal therapy less than 4 weeks from enrollment.
Participants with definitively treated non-invasive malignancies such as cervical carcinoma in situ, ductal carcinoma in situ, Grade 1 or 2, Stage I endometrial cancer, or non-melanomatous skin cancer are allowed.
Participant is at increased bleeding risk due to concurrent conditions (example, major injuries or major surgery within the past 28 days prior to start of study treatment and/or history of hemorrhagic stroke, transient ischemic attack, subarachnoid hemorrhage, or clinically significant hemorrhage within the past 3 months).
Participant is immunocompromised.
Participant has known active hepatitis B (example, hepatitis B surface antigen reactive) or hepatitis C (example, hepatitis C virus ribonucleic acid [qualitative] is detected).
Participant is considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease, or uncontrolled infection.
Participant has had investigational therapy administered within 4 weeks or within a time interval less than at least 5 half-lives of the investigational agent, whichever is longer, prior to the first scheduled day of dosing in this study.
Participant has received a live vaccine within 14 days of planned start of study therapy. Seasonal influenza vaccines that do not contain live viruses are allowed.
Participant has a known contraindication or uncontrolled hypersensitivity to the components of paclitaxel, carboplatin, niraparib, bevacizumab, dostarlimab, or their excipients.
Prior treatment for high-grade nonmucinous epithelial ovarian, fallopian tube, or peritoneal cancer (immunotherapy, anti-cancer therapy, radiation therapy).
Participant has an active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy is not considered a form of systemic therapy (example, thyroid hormone or insulin).
Participant has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of systemic immunosuppressive therapy within 7 days prior to the first dose of study treatment.

Study is for people with:

Ovarian Cancer

Phase:

Phase 3

Estimated Enrollment:

1402

Study ID:

NCT03602859

Recruitment Status:

Active, not recruiting

Sponsor:

Tesaro, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 187 Locations for this study

See Locations Near You

GSK Investigational Site
Anchorage Alaska, 99508, United States
GSK Investigational Site
Phoenix Arizona, 85016, United States
GSK Investigational Site
Tucson Arizona, 85704, United States
GSK Investigational Site
Tucson Arizona, 85710, United States
GSK Investigational Site
Tucson Arizona, 85711, United States
GSK Investigational Site
Los Angeles California, 90027, United States
GSK Investigational Site
Los Angeles California, 90048, United States
GSK Investigational Site
Newport Beach California, 92663, United States
GSK Investigational Site
Orange California, 92868, United States
GSK Investigational Site
Farmington Connecticut, 06030, United States
GSK Investigational Site
Hartford Connecticut, 06102, United States
GSK Investigational Site
Gainesville Florida, 32608, United States
GSK Investigational Site
Jacksonville Florida, 32256, United States
GSK Investigational Site
Warrenville Illinois, 60555, United States
GSK Investigational Site
Zion Illinois, 60099, United States
GSK Investigational Site
Covington Louisiana, 70433, United States
GSK Investigational Site
New Orleans Louisiana, 70121, United States
GSK Investigational Site
Shreveport Louisiana, 71103, United States
GSK Investigational Site
Scarborough Maine, 04074, United States
GSK Investigational Site
Baltimore Maryland, 21201, United States
GSK Investigational Site
Silver Spring Maryland, 20902, United States
GSK Investigational Site
Silver Spring Maryland, 20910, United States
GSK Investigational Site
Boston Massachusetts, 02215, United States
GSK Investigational Site
Springfield Massachusetts, 01199, United States
GSK Investigational Site
Worcester Massachusetts, 01605, United States
GSK Investigational Site
Maplewood Minnesota, 55109, United States
GSK Investigational Site
Minneapolis Minnesota, 55404, United States
GSK Investigational Site
Minneapolis Minnesota, 55455, United States
GSK Investigational Site
Billings Montana, 59101, United States
GSK Investigational Site
Neptune New Jersey, 07753, United States
GSK Investigational Site
Teaneck New Jersey, 07666, United States
GSK Investigational Site
Hawthorne New York, 10532, United States
GSK Investigational Site
New York New York, 10016, United States
GSK Investigational Site
New York New York, 10029, United States
GSK Investigational Site
New York New York, 10032, United States
GSK Investigational Site
New York New York, 10065, United States
GSK Investigational Site
Rochester New York, 14620, United States
GSK Investigational Site
Stony Brook New York, 11794, United States
GSK Investigational Site
Syracuse New York, 13210, United States
GSK Investigational Site
Charlotte North Carolina, 28204, United States
GSK Investigational Site
Canton Ohio, 44710, United States
GSK Investigational Site
Cincinnati Ohio, 45219, United States
GSK Investigational Site
Oklahoma City Oklahoma, 73104, United States
GSK Investigational Site
Eugene Oregon, 97401, United States
GSK Investigational Site
Portland Oregon, 97227, United States
GSK Investigational Site
Tualatin Oregon, 97062, United States
GSK Investigational Site
Abington Pennsylvania, 19001, United States
GSK Investigational Site
Paoli Pennsylvania, 19301, United States
GSK Investigational Site
Philadelphia Pennsylvania, 19111, United States
GSK Investigational Site
Pittsburgh Pennsylvania, 15224, United States
GSK Investigational Site
Pittsburgh Pennsylvania, 15232, United States
GSK Investigational Site
Wynnewood Pennsylvania, 19096, United States
GSK Investigational Site
Providence Rhode Island, 02905, United States
GSK Investigational Site
Charleston South Carolina, 29425, United States
GSK Investigational Site
Sioux Falls South Dakota, 57105, United States
GSK Investigational Site
Knoxville Tennessee, 37920, United States
GSK Investigational Site
Nashville Tennessee, 37203, United States
GSK Investigational Site
Nashville Tennessee, 37205, United States
GSK Investigational Site
Austin Texas, 78731, United States
GSK Investigational Site
Dallas Texas, 75246, United States
GSK Investigational Site
Fort Worth Texas, 76104, United States
GSK Investigational Site
Houston Texas, 77030, United States
GSK Investigational Site
San Antonio Texas, 78240, United States
GSK Investigational Site
The Woodlands Texas, 77380, United States
GSK Investigational Site
Tyler Texas, 75702, United States
GSK Investigational Site
Ogden Utah, 84405, United States
GSK Investigational Site
Charlottesville Virginia, 22903, United States
GSK Investigational Site
Hampton Virginia, 23666, United States
GSK Investigational Site
Newport News Virginia, 23606, United States
GSK Investigational Site
Norfolk Virginia, 23502, United States
GSK Investigational Site
Kennewick Washington, 99336, United States
GSK Investigational Site
Seattle Washington, 98104, United States
GSK Investigational Site
Seattle Washington, 98109, United States
GSK Investigational Site
Vancouver Washington, 98684, United States
GSK Investigational Site
Minsk , 22304, Belarus
GSK Investigational Site
Brasschaat , 2930, Belgium
GSK Investigational Site
Brugge , 8000, Belgium
GSK Investigational Site
Brussels , 1000, Belgium
GSK Investigational Site
Vancouver British Columbia, V5Z 4, Canada
GSK Investigational Site
London Ontario, N6A 4, Canada
GSK Investigational Site
Toronto Ontario, M4N 3, Canada
GSK Investigational Site
Montreal Quebec, H2X 3, Canada
GSK Investigational Site
Montreal Quebec, H4A 3, Canada
GSK Investigational Site
Sherbrooke Quebec, J1H 5, Canada
GSK Investigational Site
Prague , 128 5, Czechia
GSK Investigational Site
Praha 8 - Liben , 180 8, Czechia
GSK Investigational Site
Copenhagen , DK- 2, Denmark
GSK Investigational Site
Dk-2730 Herlev , 2730, Denmark
GSK Investigational Site
Roskilde , 4000, Denmark
GSK Investigational Site
Helsinki , 00029, Finland
GSK Investigational Site
Kuopio , 70210, Finland
GSK Investigational Site
Tampere , 33520, Finland
GSK Investigational Site
Turku , 20520, Finland
GSK Investigational Site
Angers Cedex 02 , 49055, France
GSK Investigational Site
Avignon Cedex 9 , 84918, France
GSK Investigational Site
Besançon Cedex , 25030, France
GSK Investigational Site
Bordeaux , 33000, France
GSK Investigational Site
Caen , 14000, France
GSK Investigational Site
Clermont-Ferrand cedex , 63011, France
GSK Investigational Site
Dijon Cedex , 21079, France
GSK Investigational Site
Grenoble Cedex , 38000, France
GSK Investigational Site
La Tronche , 38700, France
GSK Investigational Site
Le Mans , 72000, France
GSK Investigational Site
Lille , 59000, France
GSK Investigational Site
Lyon cedex 08 , 69373, France
GSK Investigational Site
Lyon , 69008, France
GSK Investigational Site
Marseille Cedex 9 , 13273, France
GSK Investigational Site
Montpellier Cedex 5 , 34298, France
GSK Investigational Site
Montpellier , 34070, France
GSK Investigational Site
Nancy , 54100, France
GSK Investigational Site
Nantes , 44227, France
GSK Investigational Site
Nice Cedex 2 , 06189, France
GSK Investigational Site
Nîmes cedex 9 , 30029, France
GSK Investigational Site
Paris Cedex 05 , 75248, France
GSK Investigational Site
Paris Cedex 14 , 75014, France
GSK Investigational Site
Paris Cedex 15 , 75908, France
GSK Investigational Site
Paris Cedex 20 , 75970, France
GSK Investigational Site
Paris , 75014, France
GSK Investigational Site
Paris , 75020, France
GSK Investigational Site
Pierre-Benite Cedex , 69495, France
GSK Investigational Site
Pierre-Bénite cedex , 69495, France
GSK Investigational Site
Plerin-sur-mer , 22190, France
GSK Investigational Site
Poitiers cedex , 86021, France
GSK Investigational Site
Reims Cedex , 51056, France
GSK Investigational Site
Rennes Cedex , 35042, France
GSK Investigational Site
Saint-Priest en Jarez , 42271, France
GSK Investigational Site
Strasbourg Cedex , 67091, France
GSK Investigational Site
Toulouse Cedex 9 , 31059, France
GSK Investigational Site
Tours Cedex 1 , 37044, France
GSK Investigational Site
Villejuif , 94805, France
GSK Investigational Site
Ravensburg Baden-Wuerttemberg, 88212, Germany
GSK Investigational Site
Wolfsburg Niedersachsen, 38440, Germany
GSK Investigational Site
Muenster Nordrhein-Westfalen, 48149, Germany
GSK Investigational Site
Kiel Schleswig-Holstein, 24103, Germany
GSK Investigational Site
Berlin , 13125, Germany
GSK Investigational Site
Hamburg , 22457, Germany
GSK Investigational Site
Athens , 115 2, Greece
GSK Investigational Site
Athens , 11528, Greece
GSK Investigational Site
Athens , 12462, Greece
GSK Investigational Site
Haidari, Athens , 12462, Greece
GSK Investigational Site
Maroussi , 15123, Greece
GSK Investigational Site
Beer Sheva , 84101, Israel
GSK Investigational Site
Haifa , 31096, Israel
GSK Investigational Site
Haifa , 34362, Israel
GSK Investigational Site
Holon , 58220, Israel
GSK Investigational Site
Petach Tikva , 49414, Israel
GSK Investigational Site
Rehovot , 76100, Israel
GSK Investigational Site
Napoli Campania, 80131, Italy
GSK Investigational Site
Faenza (RA) Emilia-Romagna, 48018, Italy
GSK Investigational Site
Ravenna Emilia-Romagna, 48100, Italy
GSK Investigational Site
Bologna , 40138, Italy
GSK Investigational Site
Meldola , 47014, Italy
GSK Investigational Site
Amsterdam , 1105 , Netherlands
GSK Investigational Site
Groningen , 9700 , Netherlands
GSK Investigational Site
Maastricht , 6229 , Netherlands
GSK Investigational Site
Nijmegen , 6525 , Netherlands
GSK Investigational Site
Rotterdam , 3015 , Netherlands
GSK Investigational Site
Utrecht , 3584 , Netherlands
GSK Investigational Site
Kristiansand , 4632, Norway
GSK Investigational Site
Oslo , 0310, Norway
GSK Investigational Site
Tromso , 9019, Norway
GSK Investigational Site
Olsztyn , 10-22, Poland
GSK Investigational Site
Szczecin , 70-11, Poland
GSK Investigational Site
Warszawa , 02-78, Poland
GSK Investigational Site
Bucuresti , 02232, Romania
GSK Investigational Site
Cluj-Napoca , 40001, Romania
GSK Investigational Site
Cluj-Napoca , 40005, Romania
GSK Investigational Site
Constanta , 90059, Romania
GSK Investigational Site
Craiova , 20034, Romania
GSK Investigational Site
Timisoara , 30023, Romania
GSK Investigational Site
Avila , 05071, Spain
GSK Investigational Site
Badalona , 08916, Spain
GSK Investigational Site
Barcelona , 08036, Spain
GSK Investigational Site
Girona , 17007, Spain
GSK Investigational Site
Jaén , 23007, Spain
GSK Investigational Site
Madrid , 28046, Spain
GSK Investigational Site
San Sebastian de los Reyes , 28702, Spain
GSK Investigational Site
Santiago de Compostela , 15706, Spain
GSK Investigational Site
Toledo , 45007, Spain
GSK Investigational Site
Valencia , 46010, Spain
GSK Investigational Site
Zaragoza , 50009, Spain
GSK Investigational Site
Chernihiv , 14029, Ukraine
GSK Investigational Site
Kharkiv , 61024, Ukraine
GSK Investigational Site
Lviv , 79031, Ukraine
GSK Investigational Site
Portsmouth Hampshire, PO6 3, United Kingdom
GSK Investigational Site
Sutton Surrey, SM2 5, United Kingdom
GSK Investigational Site
Bebington, Wirral , CH63 , United Kingdom
GSK Investigational Site
Glasgow , G12 0, United Kingdom
GSK Investigational Site
London , SW36J, United Kingdom
GSK Investigational Site
Truro , TR1 3, United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Ovarian Cancer

Phase:

Phase 3

Estimated Enrollment:

1402

Study ID:

NCT03602859

Recruitment Status:

Active, not recruiting

Sponsor:


Tesaro, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.